Meticulous Research® Predicts Vaccines Market to Reach $71.50 Billion by 2031

Meticulous Research Predicts Vaccines Market to Reach $71.50 Billion by 2031

Vaccines Market 2024-2031 Meticulous Research has released its latest report forecasting that the global vaccines market will reach $71.50 billion by 2031, growing at a compound annual growth rate (CAGR) of 2.3% over the forecast period. Key drivers of this market growth include a robust pipeline for vaccines, increased government immunization initiatives, and significant technological advancements in vaccine development. Additionally, the rising prevalence of various diseases, a growing focus on therapeutic vaccines, and promising growth in emerging markets present substantial opportunities for market players. Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5076 However, the market faces challenges such as the high costs associated with vaccine development and lengthy manufacturing timelines. Product recalls and limited access to vaccines further constrain market growth. 1.1.1Leading Market Players Prominent companies in the vaccines market include: Sanofi (France) Merck & Co., Inc. (U.S.) GlaxoSmithKline plc (U.K.) Pfizer Inc. (U.S.) Johnson & Johnson (U.S.) Daiichi Sankyo Co., Ltd. (Japan) Takeda Pharmaceutical Company Limited (Japan) CSL Limited (Australia) Emergent BioSolutions Inc. (U.S.) AstraZeneca PLC (U.K.) 1.1.2Market Segmentation and Future Outlook 1.1.2.1By Indication The vaccines market is segmented by indication into: Pneumococcal Disease Influenza Human Papillomavirus (HPV) Diphtheria, Tetanus, and Pertussis (DTP) Meningococcal Disease Measles, Mumps, and Rubella (MMR) Rotavirus Page 1 of 4 Meticulous Research| sales@meticulousresearch.com

Vaccines Market 2024-2031 Poliomyelitis (Polio) Hepatitis COVID-19 Other Indications Request Sample Report Here @ https://www.meticulousresearch.com/request- sample-report/cp_id=5076 In 2024, the pneumococcal disease segment is anticipated to hold the largest market share, driven by the rising incidence of diseases such as pneumonia, meningitis, febrile bacteremia, otitis media, and sinusitis, as well as the development of high- quality vaccines like PPSV23. 1.1.2.2 By Route of Administration The market is categorized by route of administration into: Intramuscular (IM) Subcutaneous (SC) Oral Other Routes The intramuscular (IM) segment is expected to dominate in 2024, attributed to the ease of administration and rapid absorption associated with this method. The COVID-19 pandemic has further bolstered the adoption of the intramuscular route, with many COVID-19 vaccines being administered this way. 1.1.2.3 By Type The vaccines market is classified by type into: Subunit & Conjugate Vaccines Inactivated Vaccines Live-Attenuated Vaccines Toxoid Vaccines Combination Vaccines In 2024, the subunit & conjugate vaccines segment is projected to lead, thanks to their long-term immunity, high safety, and stability compared to other vaccine types. 1.1.2.4 By Valence The market is divided by valence into: Page 2 of 4 Meticulous Research| sales@meticulousresearch.com

Vaccines Market 2024-2031 Multivalent Vaccines Monovalent Vaccines The multivalent vaccines segment is expected to hold a larger share in 2024, due to the launch of new multivalent vaccines, increased R&D investments, and technological advancements in their production. 1.1.3Geographic Analysis This comprehensive report provides an in-depth analysis of key regions including: North America (U.S. and Canada) Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, and Rest of Europe) Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific) Latin America (Brazil, Mexico, Rest of Latin America) Middle East & Africa North America is projected to command the largest share of the vaccines market in 2024, with a 41.2% share, followed by Europe and Asia-Pacific. The significant market presence in North America is attributed to active research & development, frequent product launches, and the establishment of new facilities by key industry players. Quick Buy @ https://www.meticulousresearch.com/Checkout/94492906 1.1.4Conclusion The vaccines market is poised for steady growth, driven by innovative advancements and increasing global health initiatives. Despite challenges, the market offers significant opportunities, particularly in emerging regions and through the development of new vaccine technologies. Meticulous Research will continue to monitor and analyze these trends, providing valuable insights to industry stakeholders. About Meticulous Research Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built Page 3 of 4 Meticulous Research| sales@meticulousresearch.com

Vaccines Market 2024-2031 strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value- driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth. Contact Us: Meticulous Research Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research Page 4 of 4 Meticulous Research| sales@meticulousresearch.com